Reply to: Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status

Lindsay M. LaFave, Wendy Béguelin, Richard Koche, Matt Teater, Barbara Spitzer, Alan Chramiec, Efthymia Papalexi, Matthew D. Keller, Todd Hricik, Katerina Konstantinoff, Jean Baptiste Micol, Benjamin Durham, Sarah K. Knutson, John E. Campbell, Gil Blum, Xinxu Shi, Emma H. Doud, Andrei V. Krivtsov, Young Rock Chung, Inna KhodosElisa De Stanchina, Ouathek Ouerfelli, Prasad S. Adusumilli, Paul Martin Thomas, Neil L Kelleher, Minkui Luo, Heike Keilhack, Omar Abdel-Wahab, Ari Melnick, Scott A. Armstrong, Ross L. Levine*

*Corresponding author for this work

Research output: Contribution to journalLetter

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)578-579
Number of pages2
JournalNature Medicine
Volume22
Issue number6
DOIs
StatePublished - Jun 7 2016

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., Micol, J. B., Durham, B., Knutson, S. K., Campbell, J. E., Blum, G., Shi, X., Doud, E. H., Krivtsov, A. V., Chung, Y. R., ... Levine, R. L. (2016). Reply to: Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. Nature Medicine, 22(6), 578-579. https://doi.org/10.1038/nm.4094